9 Analysts Have This to Say About Viking Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, 9 analysts have provided ratings for Viking Therapeutics (NASDAQ:VKTX), with 7 being bullish, 2 somewhat bullish, and none being bearish or indifferent. The company has an average 12-month price target of $33.0, with a high of $40.00 and a low of $24.00. This average price target has increased by 13.79% over the past month.
July 27, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics has received positive ratings from analysts, with an increasing 12-month price target. This could potentially boost investor confidence and positively impact the stock price in the short term.
Analyst ratings often influence investor sentiment and can impact stock prices. In this case, the majority of analysts have given Viking Therapeutics a bullish rating, and the average 12-month price target has increased over the past month. This suggests a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100